Physician profile
Vikram David Durairaj
NPI 1871683540
$378,571.99
in general payments reported to CMS, 2019-2025
28 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $25K · 2021: $70K · 2022: $124K · 2023: $7,019 · 2024: $74K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $94K · Travel and Lodging: $19K · Food and Beverage: $8,752 · Entertainment: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $93,666.25 |
| Travel and Lodging | $18,774.49 |
| Food and Beverage | $8,751.93 |
| Entertainment | $144.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $208,795.87 | 2019-2025 | Na, Vsp System, Vsp Cranial, Medpor Titan |
| Genentech USA, INC. | $127,493.95 | 2019-2025 | Vabysmo |
| Horizon Therapeutics Plc | $20,923.75 | 2020-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $10,278.28 | 2023-2024 | Cequa |
| Amgen INC. | $4,753.49 | 2024-2025 | Tepezza |
| Lumenis Be INC | $1,553.00 | 2024 | M22 |
| Tarsus Pharmaceuticals, INC. | $608.55 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $586.50 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $527.82 | 2019-2024 | Tecnis Simplicity |
| Regeneron Pharmaceuticals, INC. | $434.94 | 2022-2025 | Eylea Hd |
| New World Medical,INC. | $349.25 | 2023-2024 | Clearpath, Streamline, Kahook Dual Blade |
| Glaukos Corporation | $330.50 | 2024-2025 | Idosetr |
| Sight Sciences, INC. | $276.48 | 2024-2025 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $247.19 | 2024-2025 | Xipere, Vyzulta, Envista Mx60 Iol |
| Apellis Pharmaceuticals, INC. | $243.19 | 2024-2025 | Syfovre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $150.55 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Optos, INC. | $144.43 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $119.88 | 2024 | Clareon |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Aerie Pharmaceuticals, INC. | $117.87 | 2019 | |
| Abbvie INC. | $106.42 | 2022 | |
| Oyster Point Pharma, INC. | $106.03 | 2023 | Tyrvaya |
| Optovue, INC. | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.70 | 2019 | |
| Ani Pharmaceuticals, INC. | $31.00 | 2025 | Purified Cortrophin Gel |
| Integra Lifesciences Corporation | $28.87 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Mimedx Group, INC. | $25.25 | 2025 | |
| Allergan, INC. | $24.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Durairaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.